Abstract

A COMPREHENSIVE REVIEW ON THE DRUG PROFILE OF FLURPIRIDAZ F-18 (FLYRCADO™)

Kamalapuram Supraja Bai*

ABSTRACT

Flurpiridaz F-18 (Flyrcado™) is a novel PET imaging agent approved for myocardial perfusion imaging (MPI) in adult patients with known or suspected coronary artery disease (CAD). It offers higher image resolution, better sensitivity, and greater diagnostic accuracy compared to conventional SPECT imaging agents. Flurpiridaz is a fluorine-18–labeled radiotracer that binds selectively to mitochondrial complex I in cardiac tissue, reflecting regional myocardial perfusion. Its longer half-life, improved extraction fraction, and ability to provide high-quality images under stress and rest conditions make it a promising alternative in nuclear cardiology. Flyrcado represents a significant advance in cardiac imaging, especially for patients unable to undergo traditional exercise stress testing.

Keywords: Flurpiridaz F-18, Flyrcado™, PET imaging, myocardial perfusion imaging, coronary artery disease, cardiac diagnostics.